Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19

• Main Authors: Ainur Nurpeisova (Author), Berik Khairullin (Author), Ruslan Abitaev (Author), Kamshat Shorayeva (Author), Kuanish Jekebekov (Author), Elina Kalimolda (Author), Aslan Kerimbayev (Author), Karligash Akylbayeva (Author), Zhandos Abay (Author), Balzhan Myrzakhmetova (Author), Aziz Nakhanov (Author), Zharkinay Absatova (Author), Sergazy Nurabayev (Author), Mukhit Orynbayev (Author), Nurika Assanzhanova (Author), Khairulla Abeuov (Author), Lespek Kutumbetov (Author), Markhabat Kassenov (Author), Yergaly Abduraimov (Author), Kunsulu Zakarya (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (Macaca mulatta). The study's safety data suggests that this immunobiologic...